Akebia Therapeutics Inc. Registered Shares DL -,00001
- BID
1.119
- ASK
1.133
- 44,683 Units52,957 Units
- 07/20, 21:58:59 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
64.18%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.02 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 1.11 G | 0 Units |
| PRICE DETERMINATION TIME | 07/20/2026 / 09:55:58 PM | |
| DAILY VOLUME (UNITS) | 848 | |
| DAILY HIGH / LOW | 1.2025 | 1.11 |
| PREV. DAY'S PRICE | 1.1685 | (07/17) |
| CHANGE DAY BEFORE | -0.06 | -5.01 % |
| 52 WEEK HIGH / LOW | 3.382 (07/23) | 0.7222 (06/10) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.26 | -0.30 | -0.02 | -0.11 | -0.17 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | - | - | 13.10 | - | - |
PRICE - SALES RATIO | 1.19 | 2.50 | 1.75 | - | - |
PRICE - CASH FLOW RATIO | - | - | 6.09 | - | - |
Master Data
| WKN | A1XF0S |
| ISIN | US00972D1054 |
| SYMBOL | AX9 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | AKEBIA THERAPEUT.DL-00001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -3.83 % | 32.27 % | -1.97 % | 0.13 % | -64.18 % | 9.62 % | -56.07 % | -12.41 % |
| HIGH | 1.23 | 1.27 | 1.30 | 1.34 | 3.38 | 3.51 | 3.51 | 1.37 |
| LOW | 1.17 | 0.87 | 0.72 | 0.72 | 0.72 | 0.72 | 0.19 | 0.72 |
Dividende
pro Aktie
AKEBIA THERAPEUT.DL-00001 does not deliver dividend information
Company profile
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice Jr., Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.